Global Tardive Dyskinesia (TD) Treatment Market: Overview
Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. The side effect of the neuroleptics medicines is tardive dyskinesia. These medicines are also known as major tranquilizers or antipsychotics. These medicines are mainly used for treating mental issues. Tardive dyskinesia occurs when you are on the medication for many months or years. As the drug that can be used for the treatment of tardive dyskinesia is not approved and method of treatment is also yet not confirmed thus the treatment of the disease is a difficult task. The tardive dyskinesia treatment affects the neurological system of the patient.
Global Tardive Dyskinesia (TD) Treatment Market: Segmentation
The global market for tardive dyskinesia treatment is fragmented into drug and end-user. On the basis of the drug, the global market is segregated into valbenazine, amantadine, tetrabenazine, clonazepam, and others. On the basis of the end user, the market is categorized into pharmacies, hospitals, and drug stores.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Tardive Dyskinesia (TD) Treatment Market: Growth Factors
The market for the tardive dyskinesia treatment will grow significantly in the coming years. The key factor that is driving the tardive dyskinesia treatment market is the increasing number of people that are suffering from the neurological disorders. In North America majority of the population is suffering from tardive dyskinesia and the people are looking forward to the treatment, thus boosting the growth of the market. The factor that is hindering the market growth is the approval process of the new treatment methods by the respective association.
Global Tardive Dyskinesia (TD) Treatment Market: Regional Analysis
The global tardive dyskinesia treatment market is regionally diversified into Eastern Europe, Latin America, the Middle East & Africa, Western Europe, North America, and Asia Pacific. The region that is dominating the tardive dyskinesia treatment market is North America. The market players in the North American region actively participate in the development of the new drugs for the treatment and the research activities and also this region has the highest demand for the neurological drugs. The regions that are following North America are Europe and Asia Pacific. The factor that these regions are also actively contributing to the research activities and are taking initiatives in building awareness about the tardive dyskinesia treatment.
Global Tardive Dyskinesia (TD) Treatment Market: Competitive Players
The key market players that are involved in the tardive dyskinesia treatment market include Teva Pharmaceutical Industries Ltd., Biogen, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Neurocrine Biosciences, Inc., Pfizer Inc., Novartis AG, Sanofi, AstraZeneca, and Bayer AG.
Global Tardive Dyskinesia (TD) Treatment Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets